| |
Explore the current environment of cell therapies in solid and hematologic cancer. Discover lessons learned from the front lines of cell therapy trial conduct. Decode the nuances and strategies of oncology cell therapy research and development. Equip yourself with the knowledge to amplify your program.
Precision for Medicine – Realize More.
|
|
Today's Big NewsMay 25, 2023 |
| By Andrea Park Activist investor Carl Icahn’s proxy battle against Illumina reached its conclusion Thursday with wins and losses on both sides. |
|
|
|
By Angus Liu Before the annual ASCO meeting, Fierce Pharma gathered expectations for two important early-stage cancer studies from oncology leaders at Penn Medicine and MD Anderson Cancer Center, plus analysts at SVB Securities and Cowen. |
By Nick Paul Taylor BenevolentAI is cutting back its drug development operation in the wake of a midphase flop, laying off up to 180 staff, reducing its lab footprint, pausing some programs and dropping its lead candidate. |
By Angus Liu,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Andrea Park Though the smallest of Medtronic’s four core businesses, the diabetes department has taken center stage as of late. |
By Kevin Dunleavy In a race with Bristol Myers Squibb to advance cell therapies to treat patients at an earlier stage of multiple myeloma, Johnson & Johnson has hit another milepost. J&J and co-developer Legend Biotech have filed with the European Medicines Agency for approval of Carvykti to treat patients with relapsed and lenalidomide-refractory multiple myeloma. |
By Andrea Park Almost a year after announcing its intention to acquire a majority stake in M.I.Tech, the South Korean medtech responsible for a portfolio of gastrointestinal and airway stents, Boston Scientific is walking away from the deal. |
By Kevin Dunleavy Many employees at pharma companies find their work exhausting and are susceptible to burnout, according to a new report from workplace culture expert O.C. Tanner Institute. Among nearly 300 surveyed employees, 48% reported finding their work exhausting, with 30% feeling emotionally frustrated. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we''ll discuss the recent biopharma layoff trends, plus Elizabeth Holmes, Sarepta Therapeutics, Abbott's FDA approval, and the rest of the week's headlines. |
|
|---|
|
|
|
Friday, June 9, 2023 | 9am ET / 6am PT Plasmid DNA plays a very important role in cell and gene therapy, yet often manufacturing at large scale can present challenges for organizations looking to focus their efforts on therapeutic outcomes rather than bioprocessing roadblocks. Join this discussion to explore the latest opportunities, challenges, innovations, lessons learned and more. Register now.
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
